ICOS Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: MarkR37 who wrote (791)	11/9/2000 11:22:49 PM
From: Ian@SI	Read Replies (1) of 1139

Anyone know what the payment stream might look like for this agreement between ICOS and Seattle Genetics. Seattle Genetics Signs Development and Manufacturing Agreement With ICOS BOTHELL, Wash., Nov 9, 2000 (BW HealthWire) -- Seattle Genetics, Inc. announced today that it has signed a development and manufacturing agreement with ICOS Corporation (Nasdaq:ICOS). Under the terms of the agreement, ICOS will conduct development, scale-up and manufacturing in its cell culture manufacturing facility to provide qualified, GMP grade product for clinical testing. The drug candidate being developed is a monoclonal antibody for cancer therapy. Seattle Genetics retains the rights to commercialize the product. Terms of the agreement were not disclosed. "We are very pleased to have a close working relationship with ICOS," stated H. Perry Fell, Ph.D., Chief Executive Officer of Seattle Genetics. "This agreement exemplifies our commitment to develop drug candidates for cancer patients."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next